Literature DB >> 23821296

Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles.

Abdullah Kocabaş1, Fırat Kardelen, Halil Ertuğ, Bilge Aldemir-Kocabaş, Özgür Tosun, Akif Yeşilipek, Volkan Hazar, Gayaz Akçurin.   

Abstract

We aimed to assess early-onset chronic progressive cardiotoxicity in the left and right ventricles with increasing cumulative anthracycline doses. We evaluated 72 patients within the first year after doxorubicin and/or daunorubicin treatment (median 1.3 months; range 0.3-11.5) and 31 healthy controls. Pretreatment and posttreatment QT interval analyzes were performed in 27 newly diagnosed patients. The echocardiographic data of all examinations of 72 patients were classified into three groups according to instant cumulative anthracycline doses: treatment group (TG)-I (≤120 mg/m(2); n = 26), TG-II (120-240 mg/m(2); n = 39), and TG-III (≥240 mg/m(2); n = 40). Diastolic and systolic parameters were analyzed by conventional echocardiography and tissue Doppler imaging (TDI) and compared with those of healthy controls. The mean age for patients and controls was 8.2 ± 4.5 and 9.6 ± 4.2 years, respectively (p > 0.05). QTc dispersion significantly increased after anthracycline treatment (p = 0.02). TDI showed decreased E' velocity (p < 0.001) and E'/A' ratio (p < 0.001) at lateral tricuspid annulus segment in TG-I, and these findings continued in TG-II and -III. In addition, S' velocity decreased in TG-I, -II, and -III at lateral mitral annulus (10.5 ± 2.6 cm/s, p < 0.05; 9.9 ± 2.2 cm/s, p < 0.001; and 10.1 ± 2.3 cm/s, p < 0.01, respectively). However, decrease in left-ventricular ejection fraction was statistically significant in TG-II and -III (p < 0.001). Although myocardial performance index was significantly increased in all treatment groups in both segments, it was primarily due to significant increases in isovolumic relaxation time at the lateral tricuspid annulus and isovolumic contraction time at the lateral mitral annulus. Abnormalities in diastolic function in right ventricle and systolic function in the left ventricle were observed even with a cumulative anthracycline dose <120 mg/m(2) by TDI. In addition, anthracycline treatment led to an increase in QTc dispersion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23821296     DOI: 10.1007/s00246-013-0745-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  38 in total

1.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

2.  The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index.

Authors:  S Selim Ayhan; Kurtulus Özdemir; Mehmet Kayrak; Ahmet Bacaksiz; M Akif Vatankulu; Önder Eren; Fatih Koc; Cetin Duman; Hakan Gülec; Kenan Demir; Hatem Ari; Osman Sönmez; Hasan Gök
Journal:  Cardiol J       Date:  2012       Impact factor: 2.737

Review 3.  Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

Authors:  M I Gharib; A K Burnett
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

4.  Functional myocardial impairment in children treated with anthracyclines for cancer.

Authors:  S T Yeung; C Yoong; J Spink; A Galbraith; P J Smith
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

5.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

Review 6.  Anthracyclines in the treatment of cancer. An overview.

Authors:  G N Hortobágyi
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.

Authors:  Elly Barry; Jorge A Alvarez; Rebecca E Scully; Tracie L Miller; Steven E Lipshultz
Journal:  Expert Opin Pharmacother       Date:  2007-06       Impact factor: 3.889

8.  The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies.

Authors:  Norihiko Senju; Satoshi Ikeda; Seiji Koga; Yoshiyuki Miyahara; Kunihiro Tsukasaki; Masao Tomonaga; Shigeru Kohno
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

9.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.

Authors:  Walter J Paulus; Carsten Tschöpe; John E Sanderson; Cesare Rusconi; Frank A Flachskampf; Frank E Rademakers; Paolo Marino; Otto A Smiseth; Gilles De Keulenaer; Adelino F Leite-Moreira; Attila Borbély; István Edes; Martin Louis Handoko; Stephane Heymans; Natalia Pezzali; Burkert Pieske; Kenneth Dickstein; Alan G Fraser; Dirk L Brutsaert
Journal:  Eur Heart J       Date:  2007-04-11       Impact factor: 29.983

10.  Effects of age, sex, and race on ECG interval measurements.

Authors:  P W Macfarlane; S C McLaughlin; B Devine; T F Yang
Journal:  J Electrocardiol       Date:  1994       Impact factor: 1.438

View more
  8 in total

1.  Relevance of tricuspid annular peak systolic velocity (s') to detect systolic right-ventricular impairment after anthracycline cancer treatment in childhood.

Authors:  Gunther Gores; William Ravekes; Martin Koestenberger
Journal:  Pediatr Cardiol       Date:  2013-10-16       Impact factor: 1.655

2.  Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy.

Authors:  Fei-Yan Song; Jing Shi; Ye Guo; Chu-Jie Zhang; Yu-Chen Xu; Qun-Ling Zhang; Xian-Hong Shu; Lei-Lei Cheng
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-02       Impact factor: 2.357

3.  Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline.

Authors:  Cengiz Bayram; İlker Çetin; Betul Tavil; Nese Yarali; Filiz Ekici; Pamir Isık; Bahattin Tunc
Journal:  Pediatr Cardiol       Date:  2015-01-11       Impact factor: 1.655

4.  Evaluation of early-onset cardiotoxic effects of anthracyclines used during the treatment of childhood acute lymphoblastic leukemia by speckle-tracking echocardiography.

Authors:  Özlem Arman Bilir; İbrahim İlker Çetin; Dilek Kaçar; Can Barış Aker; Namık Yaşar Özbek; Neşe Yaralı
Journal:  Anatol J Cardiol       Date:  2022-01       Impact factor: 1.596

5.  Speckle tracking echocardiography detects decreased cardiac longitudinal function in anthracycline-exposed survivors of childhood cancer.

Authors:  Kaisa Ylänen; Anneli Eerola; Kim Vettenranta; Tuija Poutanen
Journal:  Eur J Pediatr       Date:  2016-09-13       Impact factor: 3.183

6.  Evaluation of cardiac functions and atrial electromechanical delay in children with adenotonsillar hypertrophy.

Authors:  Abdullah Kocabaş; Nergis Salman; Filiz Ekici; Ilker Cetin; Fatih Alper Akcan
Journal:  Pediatr Cardiol       Date:  2013-12-17       Impact factor: 1.655

7.  Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study.

Authors:  Adriana Linares Ballesteros; Roy Sanguino Lobo; Juan Camilo Villada Valencia; Oscar Arévalo Leal; Diana Constanza Plazas Hernández; Nelson Aponte Barrios; Iván Perdomo Ramírez
Journal:  Colomb Med (Cali)       Date:  2021-02-15

8.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.